Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

 Full screen view
Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Curve type (GR values) Curve type (relative cell counts) Experiment name Number of concentrations Cell doublings (DMSO control) GR50 GRmax GR_AOC GEC50 GRinf Hill slope (GR values) R-squared sigmoid fit (GR values) P-value sigmoid fit (GR values) R-squared flat fit (GR values) IC50 Emax AUC EC50 Einf Hill slope (relative cell counts) R-squared sigmoid fit (relative cell counts) P-value sigmoid fit (relative cell counts) R-squared flat fit (relative cell counts)
HCC70 Dactolisib 2 72
sigmoid
sigmoid
HCC70 dactolisib 0 2 72
 8 1.677
0.312
0.238
0.341
0.195
0.103
0.493
0.954
9.66e-05
NA
2.24
0.447
0.738
0.0858
0.419
0.56
0.954
9.8e-05
NA
HCC1806 Omipalisib 3 72
sigmoid
sigmoid
HCC1806 omipalisib 0 3 72
 8 3.217
0.147
-0.221
0.437
0.71
-0.707
0.559
0.981
7.41e-06
NA
0.0642
0.0481
0.54
0.0538
0.0749
0.919
0.979
9.93e-06
NA
HCC1806 Omipalisib 1 72
sigmoid
sigmoid
HCC1806 omipalisib 0 1 72
 8 2.764
0.104
-0.333
0.49
0.508
-0.746
0.577
0.98
8.23e-06
NA
0.0642
0.0481
0.54
0.0538
0.0749
0.919
0.979
9.93e-06
NA
HCC1806 Omipalisib 2 72
sigmoid
sigmoid
HCC1806 omipalisib 0 2 72
 8 2.849
0.112
-0.311
0.479
0.543
-0.739
0.573
0.98
8.07e-06
NA
0.0642
0.0481
0.54
0.0538
0.0749
0.919
0.979
9.93e-06
NA
BT-20 Everolimus 2 72
flat
flat
BT20 everolimus 0 2 72
 8 1.785
Inf
0.426
0.574
0.0
0.426
0.01
NA
NA
0.426
Inf
0.547
0.547
0.0
0.547
0.01
NA
NA
0.547
BT-20 Sirolimus 3 72
flat
flat
BT20 rapamycin 0 3 72
 8 2.661
Inf
0.54
0.46
0.0
0.54
0.01
NA
NA
0.54
Inf
0.499
0.499
0.0
0.499
0.01
NA
NA
0.499
BT-20 Sirolimus 2 72
flat
flat
BT20 rapamycin 0 2 72
 8 1.952
Inf
0.421
0.579
0.0
0.421
0.01
NA
NA
0.421
Inf
0.513
0.513
0.0
0.513
0.01
NA
NA
0.513